Cargando…

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer

Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenzo, Nat P., Meyrick, Danielle, Turner, J. Harvey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871999/
https://www.ncbi.nlm.nih.gov/pubmed/29439481
http://dx.doi.org/10.3390/diagnostics8010016
_version_ 1783309740691947520
author Lenzo, Nat P.
Meyrick, Danielle
Turner, J. Harvey
author_facet Lenzo, Nat P.
Meyrick, Danielle
Turner, J. Harvey
author_sort Lenzo, Nat P.
collection PubMed
description Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. (68)Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of (68)Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), (68)Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. (68)Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA ((177)Lu-PSMA) and alpha-emitter Actinium-225 PSMA ((225)Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology.
format Online
Article
Text
id pubmed-5871999
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58719992018-03-29 Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer Lenzo, Nat P. Meyrick, Danielle Turner, J. Harvey Diagnostics (Basel) Review Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. (68)Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of (68)Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), (68)Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. (68)Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA ((177)Lu-PSMA) and alpha-emitter Actinium-225 PSMA ((225)Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology. MDPI 2018-02-11 /pmc/articles/PMC5871999/ /pubmed/29439481 http://dx.doi.org/10.3390/diagnostics8010016 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lenzo, Nat P.
Meyrick, Danielle
Turner, J. Harvey
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
title Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
title_full Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
title_fullStr Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
title_full_unstemmed Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
title_short Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
title_sort review of gallium-68 psma pet/ct imaging in the management of prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871999/
https://www.ncbi.nlm.nih.gov/pubmed/29439481
http://dx.doi.org/10.3390/diagnostics8010016
work_keys_str_mv AT lenzonatp reviewofgallium68psmapetctimaginginthemanagementofprostatecancer
AT meyrickdanielle reviewofgallium68psmapetctimaginginthemanagementofprostatecancer
AT turnerjharvey reviewofgallium68psmapetctimaginginthemanagementofprostatecancer